Doxazosin how supplied storage and handling: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
== | ==How Supplied== | ||
Doxazosin Tablets, USP are available as white to off-white tablets for oral administration. Each tablet contains doxazosin mesylate equivalent to 1 mg, 2 mg, 4 mg or 8 mg of the active constituent, doxazosin. | Doxazosin Tablets, USP are available as white to off-white tablets for oral administration. Each tablet contains doxazosin mesylate equivalent to 1 mg, 2 mg, 4 mg or 8 mg of the active constituent, doxazosin. | ||
| Line 38: | Line 38: | ||
1 mg, 2 mg, 4 mg and 8 mg''' | 1 mg, 2 mg, 4 mg and 8 mg''' | ||
{| | |||
[[image:doxa7.png]] | |[[image:doxa7.png|600px|thumb]] | ||
|} | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref> | ||
Revision as of 18:24, 12 March 2014
| Doxazosin |
|---|
| Doxazosin®, Cardura® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Doxazosin |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
How Supplied
Doxazosin Tablets, USP are available as white to off-white tablets for oral administration. Each tablet contains doxazosin mesylate equivalent to 1 mg, 2 mg, 4 mg or 8 mg of the active constituent, doxazosin.
Doxazosin Tablets, USP are available as 1 mg (white to off-white, round, scored tablets, imprinted “APO” on one side and “093” with a partial bisect on the other side), 2 mg (white to off-white, capsule shaped, scored tablets, imprinted “APO” on one side and “094” with a partial bisect on the other side), 4 mg (white to off-white, capsule shaped, scored tablets, imprinted “APO” on one side and “095” with a partial bisect on the other side) and 8 mg (white to off-white, capsule shaped, scored tablets, imprinted “APO” on one side and “096” with a partial bisect on the other side).
Bottles of 100:
1 mg (NDC 60505-0093-0)
2 mg (NDC 60505-0094-0)
4 mg (NDC 60505-0095-0)
8 mg (NDC 60505-0096-0)
Bottles of 1,000:
1 mg (NDC 60505-0093-1)
2 mg (NDC 60505-0094-1)
4 mg (NDC 60505-0095-1)
8 mg (NDC 60505-0096-1)
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Dispense in a tight, light-resistant container [see USP].
APOTEX INC.
DOXAZOSIN TABLETS, USP
1 mg, 2 mg, 4 mg and 8 mg
 |
References
- ↑ "DOXAZOSIN TABLET [APOTEX CORP.]". Retrieved 7 March 2014.